[{"address1": "4300 El Camino Real", "address2": "Suite 210", "city": "Los Altos", "state": "CA", "zip": "94022", "country": "United States", "phone": "650 351 4495", "website": "https://unicycive.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.", "fullTimeEmployees": 12, "companyOfficers": [{"maxAge": 1, "name": "Dr. Shalabh K. Gupta M.D., MPA", "age": 50, "title": "Founder, Chairman, CEO & President", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": 1458012, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pramod  Gupta Ph.D.", "age": 63, "title": "Executive Vice President of Pharmaceutical & Business Operations", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": 779178, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John W. Townsend CPA", "age": 61, "title": "Chief Financial Officer", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": 197864, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.42, "open": 1.43, "dayLow": 1.32, "dayHigh": 1.43, "regularMarketPreviousClose": 1.42, "regularMarketOpen": 1.43, "regularMarketDayLow": 1.32, "regularMarketDayHigh": 1.43, "beta": 2.682, "forwardPE": -3.2439027, "volume": 161289, "regularMarketVolume": 161289, "averageVolume": 355561, "averageVolume10days": 393420, "averageDailyVolume10Day": 393420, "bid": 1.32, "ask": 1.35, "bidSize": 100, "askSize": 100, "marketCap": 46223352, "fiftyTwoWeekLow": 0.47, "fiftyTwoWeekHigh": 2.287, "priceToSalesTrailing12Months": 68.47904, "fiftyDayAverage": 1.22678, "twoHundredDayAverage": 0.975955, "currency": "USD", "enterpriseValue": 32788354, "floatShares": 13738415, "sharesOutstanding": 34754400, "sharesShort": 35035, "sharesShortPriorMonth": 66814, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.001, "heldPercentInsiders": 0.18403, "heldPercentInstitutions": 0.4918, "shortRatio": 0.09, "shortPercentOfFloat": 0.0011999999, "bookValue": 0.098, "priceToBook": 13.571429, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -28941000, "trailingEps": -1.47, "forwardEps": -0.41, "enterpriseToRevenue": 48.575, "enterpriseToEbitda": -1.658, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "UNCY", "underlyingSymbol": "UNCY", "shortName": "Unicycive Therapeutics, Inc.", "longName": "Unicycive Therapeutics, Inc.", "firstTradeDateEpochUtc": 1626096600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8b289956-33cd-3aa2-beed-9487631afaeb", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.33, "targetHighPrice": 6.0, "targetLowPrice": 3.0, "targetMeanPrice": 4.38, "targetMedianPrice": 4.25, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 14345000, "totalCashPerShare": 0.413, "ebitda": -19778000, "totalDebt": 866000, "quickRatio": 0.928, "currentRatio": 1.201, "totalRevenue": 675000, "debtToEquity": 25.218, "revenuePerShare": 0.034, "returnOnAssets": -0.83502, "returnOnEquity": -6.96625, "freeCashflow": -2248500, "operatingCashflow": -19928000, "grossMargins": 1.0, "operatingMargins": -29.31259, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-22"}]